Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge

Reuters

08/19

Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge

A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262938) on August 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2560213882"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560213882\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560213882?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 03:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560213882","market":"fut","top_or_hot":-1,"title":"Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262938) on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-19 03:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262938) on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"减肥药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL638Gny:1","article_id":"2560213882","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560213882","pubTimestamp":1755545056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis . The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4599":"减肥药","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK4139":"生物科技","ALT":"Altimmune, Inc."},"translate_title":"Altimmune Inc.因2b期试验结果令人失望和股价暴跌而面临集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":0.9},"content_text":"Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge\n    \n\n        A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262938) on August 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}